MX2010013484A - Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. - Google Patents

Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.

Info

Publication number
MX2010013484A
MX2010013484A MX2010013484A MX2010013484A MX2010013484A MX 2010013484 A MX2010013484 A MX 2010013484A MX 2010013484 A MX2010013484 A MX 2010013484A MX 2010013484 A MX2010013484 A MX 2010013484A MX 2010013484 A MX2010013484 A MX 2010013484A
Authority
MX
Mexico
Prior art keywords
ketorolac
pharmaceutical formulation
intranasal administration
compositions
pharmaceutically acceptable
Prior art date
Application number
MX2010013484A
Other languages
English (en)
Inventor
Whiting Roger
Thirucote Ramachandran
Original Assignee
Roxro Pharma Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roxro Pharma Inc Star filed Critical Roxro Pharma Inc Star
Publication of MX2010013484A publication Critical patent/MX2010013484A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención concierne a composiciones terapéuticas, particularmente a composiciones acuosas nebulizables, y a formulaciones en dosis unitaria que comprenden ketorolaco o a una sal aceptable farmacéuticamente, solos o en combinación con lidocaina o con una sal de ésta aceptable farmacéuticamente. Las composiciones son administradas nasalmente a un sujeto en necesidad de éstas para tratar dolor o inflamación.
MX2010013484A 2008-06-13 2009-06-11 Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. MX2010013484A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6152208P 2008-06-13 2008-06-13
US16025409P 2009-03-13 2009-03-13
PCT/US2009/047095 WO2009152369A1 (en) 2008-06-13 2009-06-11 Pharmaceutical formulation of ketorolac for intranasal administration

Publications (1)

Publication Number Publication Date
MX2010013484A true MX2010013484A (es) 2011-03-29

Family

ID=40910889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010013484A MX2010013484A (es) 2008-06-13 2009-06-11 Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.

Country Status (10)

Country Link
US (3) US20100016402A1 (es)
EP (1) EP2296625A1 (es)
JP (1) JP2011524366A (es)
KR (1) KR20110017433A (es)
CN (1) CN102137656A (es)
AU (1) AU2009257385A1 (es)
CA (1) CA2727094A1 (es)
MX (1) MX2010013484A (es)
TW (1) TW201002368A (es)
WO (1) WO2009152369A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551454B2 (en) * 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
WO2012127497A1 (en) 2011-03-04 2012-09-27 Cadila Healthcare Limited Stable pharmaceutical compositions of ketorolac or salts thereof
JP2023502282A (ja) * 2018-12-19 2023-01-24 アカスティ ファーマ ユー．エス．、インコーポレイテッド 鼻腔内リドカインの治療用組成物
WO2021173707A1 (en) * 2020-02-24 2021-09-02 Yinuoke Medicine Science Technology Company Ltd. Compositions and methods for treatment of cytokine storm and cytokine release syndrome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4778810A (en) * 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US4943587A (en) * 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
US6090368A (en) * 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US20020006961A1 (en) * 1999-05-14 2002-01-17 Katz Stanley E. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
KR20070091682A (ko) * 2004-12-23 2007-09-11 록스로 파마 인코퍼레이티드 케토롤락의 비내 투여용 치료 조성물
JP4367559B2 (ja) * 2007-08-10 2009-11-18 トヨタ自動車株式会社 車両

Also Published As

Publication number Publication date
JP2011524366A (ja) 2011-09-01
CA2727094A1 (en) 2009-12-17
EP2296625A1 (en) 2011-03-23
CN102137656A (zh) 2011-07-27
US20120329849A1 (en) 2012-12-27
TW201002368A (en) 2010-01-16
WO2009152369A1 (en) 2009-12-17
AU2009257385A1 (en) 2009-12-17
US20100016402A1 (en) 2010-01-21
US20160136089A1 (en) 2016-05-19
KR20110017433A (ko) 2011-02-21

Similar Documents

Publication Publication Date Title
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MX2007007504A (es) Composiciones terapeuticas para la administracion intranasal de ketorolaco.
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
IL242268A0 (en) Combinations and forms of administration of therapeutic factors and combined treatment
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
IN2014DN03093A (es)
MY161078A (en) Topical formulation for a jak inhibitor
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
HK1176318A1 (en) Injection device
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
MX2011008132A (es) Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis.
WO2011074015A3 (en) Composition of pharmaceutical product to treat sexual dysfunction
MX2009011900A (es) Curacion de herida diabetica.
DE602008006700D1 (es)
MX2010013484A (es) Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.
WO2009088673A3 (en) Pharmaceutical composition
MX2013003523A (es) Composicion farmaceutica de dosis baja.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal